Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy

European Urology
Eduardo SolsonaJose L Monrós

Abstract

Many phase 2 bladder-sparing programmes using transurethral resection of the bladder (TURB) plus chemotherapy or radio-chemotherapy have been undertaken, but some controversies remain. To determine the efficacy of complete TURB plus three cycles of cisplatin-based chemotherapy in selected patients with muscle-invasive bladder cancer (MIBC). A phase 2 nonrandomized trial was designed that included patients with MIBC who underwent complete TURB with positive biopsies of the tumour bed. Patients with negative biopsies of the tumour bed, with macroscopically residual tumour, with hydronephrosis, or with distant metastasis were excluded from this trial. Patients included in this trial were offered three cycles of systemic chemotherapy or radical cystectomy (RC). Clinical response (cR) was denoted by either no tumour or the presence of Ta1-Tis bladder tumour at 3-mo evaluation; clinical non-response (cNR) was denoted by cases of muscle-invasive tumour or distant metastasis. Of 146 patients who entered this trial, 75 choose the bladder-sparing programme and 71 chose RC. At 5 yr and 10 yr, the cancer-specific survival (CSS) rate was 64.5% and 59.8%, respectively, with no significant difference compared to the RC arm (p=0.544). The prog...Continue Reading

References

Nov 4, 1993·The New England Journal of Medicine·D S KaufmanJ T Efird
Jul 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claus RödelRolf Sauer
Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford

❮ Previous
Next ❯

Citations

May 19, 2009·International Urology and Nephrology·Michele Pavone-Macaluso
Dec 1, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·G SanchoJ Palou
Feb 13, 2010·Current Opinion in Oncology·Todd M Morgan, Peter E Clark
Aug 5, 2014·Current Problems in Cancer·Jong Chul ParkAndrea B Apolo
Jun 25, 2013·Actas urologicas españolas·G Lendínez-CanoE Camacho Martínez
Jan 17, 2016·Cancer·Roger ChouJohn L Gore
Jan 5, 2016·Urologic Oncology·Matthew D Lyons, Angela B Smith
Apr 22, 2015·Der Urologe. Ausg. A·C Niedworok, C Gratzke
Apr 28, 2016·Der Urologe. Ausg. A·C NiedworokA Stenzl
Jan 26, 2016·Scientific Reports·Chun-Te WuMiao-Fen Chen
Jan 22, 2020·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Judy HamadAngela Smith
Jul 1, 2018·Current Oncology Reports·Skyler B Johnson, James B Yu
Aug 1, 2012·Expert Review of Anticancer Therapy·Marc A Dall'EraChong-Xian Pan
Dec 2, 2020·Urologic Oncology·David T MiyamotoKent W Mouw
May 8, 2021·Hematology/oncology Clinics of North America·Vivek Venkatramani, Dipen Jaysukhlal Parekh
May 8, 2021·Hematology/oncology Clinics of North America·David J KonieczkowskiKent W Mouw
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BellmuntUNKNOWN ESMO Guidelines Working Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.